Your session is about to expire
← Back to Search
Brigimadlin for Solid Cancers
Study Summary
This trial is for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. It examines whether a medicine called BI 907828 can help when other treatments have been unsuccessful. Participants take the medicine regularly and are monitored for changes in their health.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have advanced lung adenocarcinoma and have tried all standard treatments.My organs are working well.I have advanced biliary tract cancer and cannot be treated with surgery or standard treatments.I can provide tissue samples for cancer gene testing.I have no health issues that would stop me from following the trial or affect the drug's evaluation.All side effects from my previous cancer treatments are mild.I have never taken brigimadlin or similar drugs targeting MDM2-p53 or MDMX-p53.I am currently experiencing bleeding or have a high risk of bleeding.My cancer has MDM2 amplification and normal TP53 according to tests.I am not taking any medications that could affect the trial's safety.You have at least one specific spot that can be measured to see if the treatment is working.My solid tumor qualifies for a specific trial group.I am fully active or can carry out light work.I do not have any other cancers that could affect this trial's results.I haven't had major surgery in the last 4 weeks and don't plan any in the next 6 months.I am 18 or older and can use two forms of birth control if needed.My solid tumor qualifies for an open trial cohort.
- Group 1: brigimadlin (BI 907828) treatment arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are currently enrolled in this experiment?
"Affirmative. According to information provided on clinicaltrials.gov, the medical trial is actively seeking qualified candidates and was initially posted in late November 2022 before its most recent update occurring on March 6th 2023. 130 participants must be sourced from a total of 18 sites for this study."
Is this research endeavor available for enrollment currently?
"Clinicaltrials.gov reveals that this clinical trial is still recruiting participants; it was initially posted on November 25th 2022 and underwent its latest revision on March 6th 2023."
Has the BI 907828 treatment arm obtained clearance from the FDA?
"Due to the lack of efficacy data, BI 907828's safety is estimated at a rating of 2. Although it has been through Phase 2 trials and there are some results indicating its security."
How many venues are providing data for this research?
"Presently, this research is occurring in 18 centres situated across Washington, Hat Yai and Bangkok. It is prudent for potential participants to select the closest location possible so as to reduce their travel costs should they choose to enroll."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger